Fecal Calprotectin Levels, Quality of Life and Workability in Patients Suffering From Ulcerative Colitis Under Adalimumab Therapy - AdaProQuo

Trial Profile

Fecal Calprotectin Levels, Quality of Life and Workability in Patients Suffering From Ulcerative Colitis Under Adalimumab Therapy - AdaProQuo

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 03 Mar 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Acronyms AdaProQuo
  • Sponsors AbbVie
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Dec 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 04 Nov 2015 Planned End Date changed from 1 Aug 2016 to 1 Mar 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top